The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses
Open accessPublished version of a preprint
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
SUMMARY HLA class I (HLA-I) glycoproteins drive immune responses by presenting antigens to cognate CD8+ T cells. This process is often hijacked by tumors and pathogens for immune evasion. Because options for restoring HLA-I antigen presentation are limited, we aimed to identify druggable HLA-I pathway targets. Using iterative genome-wide screens, we uncovered that the cell surface glycosphingolipid (GSL) repertoire determines effective HLA-I antigen presentation. We show that absence of the protease SPPL3 augmented B3GNT5 enzyme activity, resulting in upregulation of surface neolacto-series GSLs. These GSLs sterically impeded antibody and receptor interactions with HLA-I and diminished CD8+ T cell activation. Furthermore, a disturbed SPPL3-B3GNT5 pathway in glioma correlated with decreased patient survival. We show that the immunomodulatory effect could be reversed through GSL synthesis inhibition using clinically approved drugs. Overall, our study identifies a GSL signature that inhibits immune recognition and represents a potential therapeutic target in cancer, infection, and autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
The Phyre2 web portal for protein modeling, prediction and analysis
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015) · Nature Protocols · doi:10.1038/nprot.2015.053 · Cited by 9,652
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“one or multiple molecules critical in HLA-I antigen presentation (Chowell et al., 2018; Gettinger et al., 2017; Restifo et al., 1996; Sade-Feldman et al., 2017; Zaretsky et al., 2016).”
BackgroundSelf-citationEasy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
The mystery of membrane organization: composition, regulation and roles of lipid rafts
Sezgin, E., Levental, I., Mayor, S., & Eggeling, C. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.16 · Cited by 2,124
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · cited 2×
“Their primary function is to present peptide fragments from degraded proteins to the T cell receptor (TCR) of cytotoxic CD8 T cells, leading to T cell-mediated elimination of target cells (Neefjes et al., 2011; Unanue and Cerottini, 1989).”
BackgroundSelf-citationReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Self-citationPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Gene essentiality and synthetic lethality in haploid human cells
Blomen, V. A., Májek, P., Jae, L. T., Bigenzahn, J. W., Nieuwenhuis, J., Staring, J., Sacco, R., van Diemen, F. R., Olk, N., Stukalov, A., et al. (2015) · Science · doi:10.1126/science.aac7557 · Cited by 857
Self-citationPresent yourself! by MHC class I and MHC class II molecules
Rock, K. L., Reits, E., & Neefjes, J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.010 · Cited by 814 · cited 2×
“In the endoplasmic reticulum (ER), the HLA-I heavy chain and its light chain beta-2 microglobulin (b2m) assemble and are stabilized by a unique combination of the ER chaperone proteins: tapasin (TAPBP), ERp57 (PDIA3), and calreticulin (CALR) (Rock et al., 2016).”
BackgroundSelf-citationGettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787 · cited 1×
“one or multiple molecules critical in HLA-I antigen presentation (Chowell et al., 2018; Gettinger et al., 2017; Restifo et al., 1996; Sade-Feldman et al., 2017; Zaretsky et al., 2016).”
BackgroundSelf-citationHeckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2951 · Cited by 555
Research works printed but not linked: 106
- Achdout, 2008, Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins, J. Virol., 82, 8030, 10.1128/JVI.00870-08 · doi:10.1128/jvi.00870-08
- Allende, 2014, Simplifying complexity: genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function, Glycoconj. J., 31, 613, 10.1007/s10719-014-9563-5 · DOI
- Amir, 2011, Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific, Blood, 118, 6733, 10.1182/blood-2011-05-354787 · doi:10.1182/blood-2011-05-354787
- Anaya, 2016, OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs, PeerJ Comput. Sci., 2, e67, 10.7717/peerj-cs.67 · DOI · Paper page
- Andrews, 1989, Human cytomegalovirus induces stage-specific embryonic antigen 1 in differentiating human teratocarcinoma cells and fibroblasts, J. Exp. Med., 169, 1347, 10.1084/jem.169.4.1347 · DOI
- Anfossi, 2006, Human NK cell education by inhibitory receptors for MHC class I, Immunity, 25, 331, 10.1016/j.immuni.2006.06.013 · DOI · Paper page
- Barbosa, 1987, Site-directed mutagenesis of class I HLA genes. Role of glycosylation in surface expression and functional recognition, J. Exp. Med., 166, 1329, 10.1084/jem.166.5.1329 · doi:10.1084/jem.166.5.1329
- Berman, 2000, The Protein Data Bank, Nucleic Acids Res., 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
- Blees, 2017, Structure of the human MHC-I peptide-loading complex, Nature, 551, 525, 10.1038/nature24627 · DOI · Paper page
- Borges, 1997, A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules, J. Immunol., 159, 5192, 10.4049/jimmunol.159.11.5192 · DOI · Paper page
- Brameshuber, 2018, Monomeric TCRs drive T cell antigen recognition, Nat. Immunol., 19, 487, 10.1038/s41590-018-0092-4 · DOI
- Brockmann, 2017, Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling, Nature, 546, 307, 10.1038/nature22376 · DOI · Paper page
- Caffaro, 2006, Nucleotide sugar transporters of the Golgi apparatus: from basic science to diseases, Acc. Chem. Res., 39, 805, 10.1021/ar0400239 · DOI
- Carette, 2009, Haploid genetic screens in human cells identify host factors used by pathogens, Science, 326, 1231, 10.1126/science.1178955 · DOI · Paper page
- Catalaa, 2006, Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas, NMR Biomed., 19, 463, 10.1002/nbm.1059 · DOI
- Ceroni, 2008, GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans, J. Proteome Res., 7, 1650, 10.1021/pr7008252 · DOI · Paper page
- Colonna, 1997, A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells, J. Exp. Med., 186, 1809, 10.1084/jem.186.11.1809 · DOI · Paper page
- Contreras, 2012, Molecular recognition of a single sphingolipid species by a protein’s transmembrane domain, Nature, 481, 525, 10.1038/nature10742 · DOI · Paper page
- Cooper, 2001, GlycoMod—a software tool for determining glycosylation compositions from mass spectrometric data, Proteomics, 1, 340, 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B · DOI · Paper page
- Cosman, 1997, A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules, Immunity, 7, 273, 10.1016/S1074-7613(00)80529-4 · DOI · Paper page
- D’Angelo, 2013, Glycosphingolipids: synthesis and functions, FEBS J., 280, 6338, 10.1111/febs.12559 · DOI · Paper page
- Davis, 2015, Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins, Cell Rep., 11, 1727, 10.1016/j.celrep.2015.05.026 · DOI
- de Groot, 2016, Complex MHC Class I Gene Transcription Profiles and Their Functional Impact in Orangutans, J. Immunol., 196, 750, 10.4049/jimmunol.1500820 · doi:10.4049/jimmunol.1500820
- de Waard, 2020, PAKC: A novel Panel of HLA class I Antigen presentation machinery Knockout Cells from the same genetic origin, Eur. J. Immunol., 10.1101/2020.01.24.917807 · doi:10.1101/2020.01.24.917807
- Dersh, 2020, Genome-wide Screens Identify Lineage- and TumorSpecific Genes Modulating MHC-I- and MHC-IIRestricted Immunosurveillance of Human Lymphomas, Immunity
- Desai, 2000, Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains, J. Immunol., 165, 3275, 10.4049/jimmunol.165.6.3275 · DOI
- Domon, 1988, Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry, Biochemistry, 27, 1534, 10.1021/bi00405a021 · doi:10.1021/bi00405a021
- Duquesnoy, 2013, Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays, Hum. Immunol., 74, 1271, 10.1016/j.humimm.2013.05.016 · DOI
- Duquesnoy, 2012, Structural aspects of human leukocyte antigen class I epitopes detected by human monoclonal antibodies, Hum. Immunol., 73, 267, 10.1016/j.humimm.2011.11.011 · DOI
- Fantini, 2000, Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion, Glycoconj. J., 17, 199, 10.1023/A:1026537122903 · DOI
- Fluhrer, 2007, Signal peptide peptidases and gamma-secretase: cousins of the same protease family?, Neurodegener. Dis., 4, 112, 10.1159/000101835 · DOI
- Fröhlich, 2015, The GARP complex is required for cellular sphingolipid homeostasis, eLife, 4, e08712, 10.7554/eLife.08712 · DOI · Paper page
- Furukawa, 2015, Comprehensive Glycomics of a Multistep Human Brain Tumor Model Reveals Specific Glycosylation Patterns Related to Malignancy, PLoS ONE, 10, e0128300, 10.1371/journal.pone.0128300 · DOI
- Gao, 1997, Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2, Nature, 387, 630, 10.1038/42523 · DOI · Paper page
- Gao, 2009, Accurate detection and complete tracking of large populations of features in three dimensions, Opt. Express, 17, 4685, 10.1364/OE.17.004685 · DOI · Paper page
- Garstka, 2015, The first step of peptide selection in antigen presentation by MHC class I molecules, Proc. Natl. Acad. Sci. USA, 112, 1505, 10.1073/pnas.1416543112 · DOI
- Ghisaidoobe, 2014, Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors, J. Med. Chem., 57, 9096, 10.1021/jm501181z · DOI
- Gonen-Gross, 2010, Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface, PLoS ONE, 5, e8941, 10.1371/journal.pone.0008941 · DOI
- Griffioen, 2012, Identification of 4 novel HLA-B∗40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity, Haematologica, 97, 1196, 10.3324/haematol.2011.049478 · doi:10.3324/haematol.2011.049478
- Hähnel, 2008, Targeting AKT signaling sensitizes cancer to cellular immunotherapy, Cancer Res., 68, 3899, 10.1158/0008-5472.CAN-07-6286 · DOI · Paper page
- Hakomori, 1984, Tumor-associated carbohydrate antigens, Annu. Rev. Immunol., 2, 103, 10.1146/annurev.iy.02.040184.000535 · doi:10.1146/annurev.iy.02.040184.000535 · Paper page
- Hansen, 2009, MHC class I antigen presentation: learning from viral evasion strategies, Nat. Rev. Immunol., 9, 503, 10.1038/nri2575 · DOI · Paper page
- Haworth, 2015, Going back to class I: MHC and immunotherapies for childhood cancer, Pediatr. Blood Cancer, 62, 571, 10.1002/pbc.25359 · DOI
- Hiby, 2010, Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2, J. Clin. Invest., 120, 4102, 10.1172/JCI43998 · DOI · Paper page
- Hogan, 1992, Localization and characterization of serologic epitopes on HLA-A2, Hum. Immunol., 33, 185, 10.1016/0198-8859(92)90070-4 · doi:10.1016/0198-8859(92)90070-4
- Jensen, 2012, Structural analysis of N- and O-glycans released from glycoproteins, Nat. Protoc., 7, 1299, 10.1038/nprot.2012.063 · DOI · Paper page
- Jongsma, 2019, The regulatory network behind MHC class I expression, Mol. Immunol., 113, 16, 10.1016/j.molimm.2017.12.005 · DOI · Paper page
- Karlsson, 2004, Negative ion graphitised carbon nano-liquid chromatography/mass spectrometry increases sensitivity for glycoprotein oligosaccharide analysis, Rapid Commun. Mass Spectrom., 18, 2282, 10.1002/rcm.1626 · DOI
- Kingsley, 1986, Three types of low density lipoprotein receptor-deficient mutant have pleiotropic defects in the synthesis of N-linked, O-linked, and lipid-linked carbohydrate chains, J. Cell Biol., 102, 1576, 10.1083/jcb.102.5.1576 · DOI · Paper page
- Kuhn, 2015, Secretome analysis identifies novel signal Peptide peptidase-like 3 (Sppl3) substrates and reveals a role of Sppl3 in multiple Golgi glycosylation pathways, Mol. Cell. Proteomics, 14, 1584, 10.1074/mcp.M115.048298 · DOI · Paper page
- Lachmann, 2003, Miglustat. Oxford GlycoSciences/Actelion, Curr. Opin. Investig. Drugs, 4, 472
- Ladasky, 1999, Residue 3 of beta2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody, Immunogenetics, 49, 312, 10.1007/s002510050498 · doi:10.1007/s002510050498
- Li, 2012, Crystal structure of adenovirus E3-19K bound to HLA-A2 reveals mechanism for immunomodulation, Nat. Struct. Mol. Biol., 19, 1176, 10.1038/nsmb.2396 · DOI
- Liu, 2013, Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance, Adv. Cancer Res., 117, 59, 10.1016/B978-0-12-394274-6.00003-0 · DOI · Paper page
- Logtenberg, 2019, Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy, Nat. Med., 25, 612, 10.1038/s41591-019-0356-z · DOI · Paper page
- Marrari, 2010, Human monoclonal antibody reactivity with human leukocyte antigen class I epitopes defined by pairs of mismatched eplets and self-eplets, Transplantation, 90, 1468, 10.1097/TP.0b013e3182007b74 · doi:10.1097/tp.0b013e3182007b74
- Merrill, 2017, Opinion article on lipidomics: Inherent challenges of lipidomic analysis of sphingolipids, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1862, 774, 10.1016/j.bbalip.2017.01.009 · DOI
- Miller-Podraza, 1993, New method for the isolation of polyglycosylceramides from human erythrocyte membranes, Biochim. Biophys. Acta, 1168, 330, 10.1016/0005-2760(93)90190-K · doi:10.1016/0005-2760(93)90190-k
- Miller-Podraza, 1997, Screening for the presence of polyglycosylceramides in various tissues: partial characterization of blood group-active complex glycosphingolipids of rabbit and dog small intestines, Glycoconj. J., 14, 231, 10.1023/A:1018545922728 · DOI
- Mitra, 2004, Supine orientation of a murine MHC class I molecule on the membrane bilayer, Curr. Biol., 14, 718, 10.1016/j.cub.2004.04.004 · DOI
- Moesta, 2008, Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3, J. Immunol., 180, 3969, 10.4049/jimmunol.180.6.3969 · DOI · Paper page
- Moore, 2008, Differential regulation of GM1 and asialo-GM1 expression by T cells and natural killer (NK) cells in respiratory syncytial virus infection, Viral Immunol., 21, 327, 10.1089/vim.2008.0003 · doi:10.1089/vim.2008.0003
- Mulder, 2010, Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation, Mol. Immunol., 47, 809, 10.1016/j.molimm.2009.10.004 · DOI
- Neefjes, 1990, N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response, J. Exp. Med., 171, 583, 10.1084/jem.171.2.583 · DOI
- Ogretmen, 2004, Biologically active sphingolipids in cancer pathogenesis and treatment, Nat. Rev. Cancer, 4, 604, 10.1038/nrc1411 · DOI · Paper page
- Oostvogels, 2014, Identification of minor histocompatibility antigens based on the 1000 Genomes Project, Haematologica, 99, 1854, 10.3324/haematol.2014.109801 · DOI
- Ovesný, 2014, ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging, Bioinformatics, 30, 2389, 10.1093/bioinformatics/btu202 · DOI · Paper page
- Pech, 2019, Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance, eLife, 8, e47362, 10.7554/eLife.47362 · DOI
- Platt, 1994, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J. Biol. Chem., 269, 8362, 10.1016/S0021-9258(17)37202-2 · DOI · Paper page
- Plomp, 2014, Site-specific N-glycosylation analysis of human immunoglobulin e, J. Proteome Res., 13, 536, 10.1021/pr400714w · DOI
- Potapenko, 2015, Glycan-related gene expression signatures in breast cancer subtypes; relation to survival, Mol. Oncol., 9, 861, 10.1016/j.molonc.2014.12.013 · DOI
- Purbhoo, 2004, T cell killing does not require the formation of a stable mature immunological synapse, Nat. Immunol., 5, 524, 10.1038/ni1058 · DOI · Paper page
- Radsak, 1984, Glycosphingolipid synthesis in human fibroblasts infected by cytomegalovirus, Virology, 138, 300, 10.1016/0042-6822(84)90353-2 · doi:10.1016/0042-6822(84)90353-2
- Reiser, 2014, Analysis of relationships between peptide/MHC structural features and naive T cell frequency in humans, J. Immunol., 193, 5816, 10.4049/jimmunol.1303084 · DOI
- Restifo, 1996, Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy, J. Natl. Cancer Inst., 88, 100, 10.1093/jnci/88.2.100 · DOI · Paper page
- Rigau, 2020, Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells, Science, 367, eaay5516, 10.1126/science.aay5516 · DOI · Paper page
- Righi, 2009, 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas, NMR Biomed., 22, 629, 10.1002/nbm.1377 · DOI
- Rocha, 2009, Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning, J Cell Biol, 185, 1209, 10.1083/jcb.200811005 · DOI · Paper page
- Roszkowski, 2003, CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell, J. Immunol., 170, 2582, 10.4049/jimmunol.170.5.2582 · DOI
- Ryan, 2012, Roles for major histocompatibility complex glycosylation in immune function, Semin. Immunopathol., 34, 425, 10.1007/s00281-012-0309-9 · DOI
- Saverino, 2000, The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions, J. Immunol., 165, 3742, 10.4049/jimmunol.165.7.3742 · DOI · Paper page
- Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 · DOI · Paper page
- Schütz, 1997, Single-molecule microscopy on model membranes reveals anomalous diffusion, Biophys. J., 73, 1073, 10.1016/S0006-3495(97)78139-6 · DOI · Paper page
- Shayman, 2010, ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease, Drugs Future, 35, 613, 10.1358/dof.2010.35.8.1505566 · DOI
- Shi, 2011, Plasticity of human CD8αα binding to peptide-HLA-A∗2402, Mol. Immunol., 48, 2198, 10.1016/j.molimm.2011.05.009 · doi:10.1016/j.molimm.2011.05.009
- Spaapen, 2008, Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis, J. Exp. Med., 205, 2863, 10.1084/jem.20080713 · DOI
- Stirnemann, 2017, A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments, Int. J. Mol. Sci., 18, 441, 10.3390/ijms18020441 · DOI · Paper page
- Taketani, 1983, Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant, J. Immunol., 131, 2935, 10.4049/jimmunol.131.6.2935 · DOI
- Thor Straten, 2016, Targetless T cells in cancer immunotherapy, J. Immunother. Cancer, 4, 23, 10.1186/s40425-016-0127-z · DOI
- Trymbulak, 1997, Mutants of human beta2-microglobulin map an immunodominant epitope within the three-stranded beta-pleated sheet, Transplantation, 64, 640, 10.1097/00007890-199708270-00016 · doi:10.1097/00007890-199708270-00016
- Unanue, 1989, Antigen presentation, FASEB J., 3, 2496, 10.1096/fasebj.3.13.2572499 · doi:10.1096/fasebj.3.13.2572499
- Valiante, 1997, Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors, Immunity, 7, 739, 10.1016/S1074-7613(00)80393-3 · DOI · Paper page
- van Bergen, 2007, Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene, Blood, 109, 4089, 10.1182/blood-2006-08-043935 · DOI
- Van Bergen, 2010, High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning, Cancer Res., 70, 9073, 10.1158/0008-5472.CAN-10-1832 · DOI
- Voss, 2012, Foamy virus envelope protein is a substrate for signal peptide peptidase-like 3 (SPPL3), J. Biol. Chem., 287, 43401, 10.1074/jbc.M112.371369 · DOI
- Voss, 2014, Shedding of glycan-modifying enzymes by signal peptide peptidase-like 3 (SPPL3) regulates cellular N-glycosylation, EMBO J., 33, 2890, 10.15252/embj.201488375 · DOI · Paper page
- Voss, 2013, Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases, Biochim. Biophys. Acta, 1828, 2828, 10.1016/j.bbamem.2013.03.033 · DOI
- Wang, 2012, High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients, Glycobiology, 22, 930, 10.1093/glycob/cws061 · DOI
- Wearsch, 2008, The quality control of MHC class I peptide loading, Curr. Opin. Cell Biol., 20, 624, 10.1016/j.ceb.2008.09.005 · DOI · Paper page
- Wieser, 2007, (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy, Biophys. J., 92, 3719, 10.1529/biophysj.106.095398 · DOI
- Wikstrand, 1991, Occurrence of lacto series gangliosides 3′-isoLM1 and 3′,6′-isoLD1 in human gliomas in vitro and in vivo, J. Neuropathol. Exp. Neurol., 50, 756, 10.1097/00005072-199111000-00007 · doi:10.1097/00005072-199111000-00007
- Willcox, 2003, Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor, Nat. Immunol., 4, 913, 10.1038/ni961 · DOI · Paper page
- Wraith, 2009, New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat, Ther. Clin. Risk Manag., 5, 877, 10.2147/TCRM.S5777 · DOI · Paper page
- Yewdell, 2002, Viral interference with antigen presentation, Nat. Immunol., 3, 1019, 10.1038/ni1102-1019 · DOI · Paper page
- Zhang, 2019, The Role of Glycosphingolipids in Immune Cell Functions, Front. Immunol., 10, 90, 10.3389/fimmu.2019.00090 · DOI · Paper page
- Zhang, 2020, The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I, bioRxiv
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“There are FDA approved inhibitors of glycosyltransferases, and these agents were shown to reverse the suppression of MHC I stimulatory activity caused by the increase in negatively charged glycosphingolipids from loss of SPPL3 (212).”
BackgroundInfluentialAntigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
Yang, J., Guo, F., Chin, H. S., Chen, G. B., Ang, C. H., Lin, Q., Hong, W., & Fu, N. Y. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112065 · Cited by 22
Metadata
- Authors
- Jongsma, M. L. M., de Waard, A. A., Raaben, M., Zhang, T., Cabukusta, B., Platzer, R., Blomen, V. A., Xagara, A., Verkerk, T., Bliss, S., Kong, X., Gerke, C., Janssen, L., Stickel, E., Holst, S., Plomp, R., Mulder, A., Ferrone, S., Claas, F. H. J., Heemskerk, M. H. M., Griffioen, M., Halenius, A., Overkleeft, H., Huppa, J. B., Wuhrer, M., Brummelkamp, T. R., Neefjes, J., & Spaapen, R. M.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 54
- Issue
- 1
- Pages
- 132-150.e9
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W3106908673
- Cited by
- 108
- References
- 19
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-02-09)
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 376 d)
- Funders
- Vienna Science and Technology Fund (LS14-031)
- U.S. Department of Defense (W81XWMH-16-1-0500)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (ZonMw-ETH 435004024)
- Landsteiner Foundation for Blood Transfusion Research (1842F)
- Boehringer Ingelheim Fonds
- Cancer Genomics Centre
- European Molecular Biology Organization (ASTF 10-2016)
- KWF Kankerbestrijding (2015-7982, NKI2015-7609)
- National Institutes of Health (R01DE028172, RO3CA223886, RO3CA231766, R03CA216114)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.